Shi-Yi Wang1,2, Jessica B Long3,4, Brigid K Killelea3,5, Suzanne B Evans3,6, Kenneth B Roberts3,6, Andrea L Silber3,7, Amy J Davidoff3,8, Tannaz Sedghi3, Cary P Gross3,4. 1. Department of Chronic Disease Epidemiology, Yale University School of Public Health, 60 College Street, P.O. Box 208034, New Haven, CT, 06520, USA. shiyi.wang@yale.edu. 2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA. shiyi.wang@yale.edu. 3. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, USA. 4. Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 5. Department of Surgery, Yale University School of Medicine, New Haven, CT, USA. 6. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA. 7. Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 8. Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA.
Abstract
PURPOSE: To examine associations between pre-operative magnetic resonance imaging (MRI) use and clinical outcomes among women undergoing breast-conserving surgery (BCS) with or without radiotherapy for early-stage breast cancer. METHODS: We identified women from the Surveillance, Epidemiology, and End Results-Medicare dataset aged 67-94 diagnosed during 2004-2010 with stage I/II breast cancer who received BCS. We compared subsequent mastectomy and breast cancer mortality with versus without pre-operative MRI, using Cox regression and competing risks models. We further stratified by receipt of radiotherapy for subgroup analyses. RESULTS: Our sample consisted of 24,379 beneficiaries, 4691 (19.2%) of whom received pre-operative MRI. Adjusted rates of subsequent mastectomy and breast cancer mortality were not significantly different with and without MRI: 3.2 versus 4.1 per 1000 person-years [adjusted hazard ratio (AHR) 0.92; 95% confidence interval (CI) 0.70-1.19] and 5.3 versus 8.7 per 1000 person-years (AHR 0.89; 95% CI 0.73-1.08), respectively. In subgroup analyses, women receiving BCS plus radiotherapy had similar rates of subsequent mastectomy (AHR 1.17; 95% CI 0.84-1.61) and breast cancer mortality (AHR 1.00; 95% CI 0.80-1.24) with versus without MRI. However, among women receiving BCS alone, MRI use was associated with lower risks of subsequent mastectomy (AHR 0.60; 95% CI 0.37-0.98) and breast cancer mortality (AHR 0.57; 95% CI 0.36-0.92). CONCLUSIONS: Pre-operative MRI was associated with improved outcomes among older women with breast cancer receiving BCS alone, but not among those receiving BCS plus radiotherapy. Further research is needed to identify appropriate settings for which MRI may be helpful.
PURPOSE: To examine associations between pre-operative magnetic resonance imaging (MRI) use and clinical outcomes among women undergoing breast-conserving surgery (BCS) with or without radiotherapy for early-stage breast cancer. METHODS: We identified women from the Surveillance, Epidemiology, and End Results-Medicare dataset aged 67-94 diagnosed during 2004-2010 with stage I/II breast cancer who received BCS. We compared subsequent mastectomy and breast cancer mortality with versus without pre-operative MRI, using Cox regression and competing risks models. We further stratified by receipt of radiotherapy for subgroup analyses. RESULTS: Our sample consisted of 24,379 beneficiaries, 4691 (19.2%) of whom received pre-operative MRI. Adjusted rates of subsequent mastectomy and breast cancer mortality were not significantly different with and without MRI: 3.2 versus 4.1 per 1000 person-years [adjusted hazard ratio (AHR) 0.92; 95% confidence interval (CI) 0.70-1.19] and 5.3 versus 8.7 per 1000 person-years (AHR 0.89; 95% CI 0.73-1.08), respectively. In subgroup analyses, women receiving BCS plus radiotherapy had similar rates of subsequent mastectomy (AHR 1.17; 95% CI 0.84-1.61) and breast cancer mortality (AHR 1.00; 95% CI 0.80-1.24) with versus without MRI. However, among women receiving BCS alone, MRI use was associated with lower risks of subsequent mastectomy (AHR 0.60; 95% CI 0.37-0.98) and breast cancer mortality (AHR 0.57; 95% CI 0.36-0.92). CONCLUSIONS: Pre-operative MRI was associated with improved outcomes among older women with breast cancer receiving BCS alone, but not among those receiving BCS plus radiotherapy. Further research is needed to identify appropriate settings for which MRI may be helpful.
Authors: Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon Journal: Lancet Oncol Date: 2015-01-28 Impact factor: 41.316
Authors: Shi-Yi Wang; Jessica B Long; Brigid K Killelea; Suzanne B Evans; Kenneth B Roberts; Andrea Silber; Cary P Gross Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Amy J Davidoff; Ilene H Zuckerman; Naimish Pandya; Franklin Hendrick; Xuehua Ke; Arti Hurria; Stuart M Lichtman; Arif Hussain; Jonathan P Weiner; Martin J Edelman Journal: J Geriatr Oncol Date: 2013-04 Impact factor: 3.599
Authors: Benjamin D Smith; Cary P Gross; Grace L Smith; Deron H Galusha; Justin E Bekelman; Bruce G Haffty Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Shi-Yi Wang; Karen M Kuntz; Todd M Tuttle; David R Jacobs; Robert L Kane; Beth A Virnig Journal: Breast Cancer Res Treat Date: 2013-01-25 Impact factor: 4.872
Authors: Tomasz P Srokowski; Shenying Fang; Zhigang Duan; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin; Sharon H Giordano Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321